CD274 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), chemotherapy combined with PD-1/PD-L1 inhibitors significantly improved progression-free survival, paving the way for integrating L-ASNase in future combinatorial protocols (152).